Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Zentalis Pharmaceuticals announced its Q1 2026 financial results and significant clinical advancements for its WEE1 inhibitor, azenosertib. The company...
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. announced its financial results for the first quarter of 2026, reporting a net loss of $12.7 million, an increase from $6.8...
BridgeBio Stands Up to Pfizer in ATTR-CM with Late-Stage Data
BridgeBio’s transthyretin amyloidosis drug Attruby elicited notable improvements in survival and hospitalization rates, pointing to its potential “superiority”...
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Verrica Pharmaceuticals announced its first-quarter 2026 financial results, showcasing significant growth for its commercial product, YCANTH (VP-102), for...
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kura Oncology and Kyowa Kirin announced updated results from the Phase 1 KOMET-007 trial, evaluating ziftomenib in combination with cytarabine plus...
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its first quarter 2026 financial results and provided a comprehensive business update, highlighting significant advancements in...
Clinical Trial Updates13 May 2026
Zentalis Pharmaceuticals announced its Q1 2026 financial results and significant clinical advancements for its WEE1 inhibitor, azenosertib. The company...
Clinical Trial Updates13 May 2026
Eupraxia Pharmaceuticals Inc. announced its financial results for the first quarter of 2026, reporting a net loss of $12.7 million, an increase from $6.8...
Clinical Trial Updates13 May 2026
BridgeBio’s transthyretin amyloidosis drug Attruby elicited notable improvements in survival and hospitalization rates, pointing to its potential “superiority”...
Clinical Trial Updates13 May 2026
Verrica Pharmaceuticals announced its first-quarter 2026 financial results, showcasing significant growth for its commercial product, YCANTH (VP-102), for...
Clinical Trial Updates13 May 2026
Kura Oncology and Kyowa Kirin announced updated results from the Phase 1 KOMET-007 trial, evaluating ziftomenib in combination with cytarabine plus...
Clinical Trial Updates13 May 2026
Atea Pharmaceuticals reported its first quarter 2026 financial results and provided a comprehensive business update, highlighting significant advancements in...
Regulatory Approvals12 May 2026
On May 11, 2026, the U.S. Food and Drug Administration announced it is soliciting public input on efforts to advance drug repurposing to address unmet medical...
Regulatory Approvals12 May 2026
aTyr Pharma announced its path forward for efzofitimod in pulmonary sarcoidosis after receiving official minutes from a Type C meeting with the U.S. Food and...
Regulatory Approvals11 May 2026
Sanofi has reportedly requested the FDA remove its type 1 diabetes drug, teplizumab (Tzield), from the Commissioner’s National Priority Review (CNPV) program....
Regulatory Approvals11 May 2026
The FDA has reversed its previous rejections of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo, for Epstein-Barr virus-positive...
Regulatory Approvals11 May 2026
Lexicon Pharmaceuticals reported its first-quarter 2026 financial results and provided key clinical updates across its cardiometabolic pipeline. The company...
Regulatory Approvals07 May 2026
A single case of hepatic failure associated with Eli Lilly’s weight-loss pill Foundayo was reported in the FDA’s Adverse Event Reporting System (FAERS),...
Mergers and Acquisitions13 May 2026
Bristol Myers Squibb (BMS) and Hengrui Pharma have announced a strategic partnership to develop 13 investigational therapies for various cancers,...
Mergers and Acquisitions13 May 2026
Arvinas and Pfizer have completed a licensing deal to transfer ownership of their recently approved breast cancer drug, Veppanu, to Rigel Pharmaceuticals. The...
Mergers and Acquisitions13 May 2026
Recordati reported strong financial results for the first quarter of 2026, with consolidated net revenue reaching €713.4 million, a 4.9% increase (+8.7%...
Mergers and Acquisitions12 May 2026
GSK has entered into an agreement with Sino Biopharmaceutical to enhance the distribution and promotion of its experimental hepatitis B drug, bepirovirsen, in...
Mergers and Acquisitions12 May 2026
Cronos Group Inc. announced strong first-quarter 2026 business results, reporting a 40% year-over-year increase in net revenue to $45.2 million and a 39% rise...
Mergers and Acquisitions11 May 2026
Angelini Pharma announced its intent to acquire Catalyst Pharmaceuticals in a $4.1 billion deal on May 7, 2026. This acquisition will provide the Italian...
Pharma competitive intelligence04 May 2026
Explains how pharma teams are shifting from quarterly reports to real-time signals for competitive intelligence, improving visibility and faster decision-making.
04 May 2026
Explains how clinical trial intelligence is reducing manual landscape analysis in drug development, improving speed, consistency, and planning decisions.
AI authoring platform04 May 2026
Explains how AI authoring platforms help create living, traceable regulatory submissions in life sciences, supporting consistency, updates, and compliance.
enterprise AI platform29 Apr 2026
An enterprise AI platform enables organizations to build, deploy, and manage AI solutions at scale. Learn how to evaluate trusted, explainable AI systems that meet compliance and transparency requirements in regulated industries.
KnolPersona31 Mar 2026
The EU Joint Clinical Assessment (JCA) regulation became mandatory for these product classes, creating a single EU-level clinical assessment that runs in parallel with the EMA regulatory review, not after it. For pharma teams accustomed to beginning HTA dossier preparation following regulatory approval, this is a strategic and operational discontinuity of the first order.
competitive intelligence29 Mar 2026
In the pharmaceutical industry, where a single competitor's Phase III readout can reshape a multi-billion dollar market overnight, the difference between knowing first and knowing last is not a matter of competitive preference. It is a matter of commercial survival.
Private by design. Speaks your language. Proven at scale
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
